Alnylam Pharmaceuticals
ALNY
#584
Rank
ยฃ26.79 B
Marketcap
ยฃ208.69
Share price
-0.89%
Change (1 day)
46.27%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of June 2024 : ยฃ0.99 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is ยฃ0.99 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31ยฃ1.02 B-6.11%
2022-12-31ยฃ1.09 B48.05%
2021-12-31ยฃ0.73 B93.07%
2020-12-31ยฃ0.38 B66.75%
2019-12-31ยฃ0.22 B873.74%
2018-12-31ยฃ23.51 M5.92%
2017-12-31ยฃ22.19 M-81.74%
2016-12-31ยฃ0.12 B
2007-12-31ยฃ3.38 M-27.43%
2006-12-31ยฃ4.66 M8.77%
2005-12-31ยฃ4.28 M14.23%
2004-12-31ยฃ3.75 M258.15%
2003-12-31ยฃ1.04 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
ยฃ89.98 M-90.94%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.06 B 107.38%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.04 B 5.08%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.20 B-79.33%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.51 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ22.08 B 2,123.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ19.40 B 1,852.96%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ14.41 B 1,351.41%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel